Image Source: Company website
- Radiopharm Theranostics has collaborated with GenesisCare to conduct its first Phase 1 trial in Australia.
- The trial for the Company’s innovative radiopharmaceutical therapy will target non-small cell lung cancer at Australian clinical research centres secured by GenesisCare.
- The trial is expected to be the first-ever human clinical trial with a RAD Therapeutic Radiopharmaceutical.
- If successful, the trial will set the stage for expanded development in lung cancer patients.
- The Company aims to bring a first-in-class treatment to the market for this area of high unmet need.
Radiopharm Theranostics Limited (ASX:RAD) has signed a Letter of Intent (LOI) with global oncology provider GenesisCare to conduct its first Phase 1 trial in Australia.
With this development, Radiopharm has set in motion the trialling of its innovative and promising radiopharmaceutical therapies. The trial will involve the Company’s proprietary nanobody from its Nano-mAbs platform, which will target the PDL1 expression in non-small cell lung cancer. It is the most common type of lung cancer and an area of high unmet need.
Radiopharm is engaged in the development of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, while GenesisCare is a leading provider of integrated oncology care globally.
As of today, radiopharmaceutical treatments have predominantly been used only for treating prostate cancer and neuroendocrine tumours. The Company is aiming to expand the nuclear medicine treatment paradigm to new therapeutic areas.
Image source: © Bearsky23 | Megapixl.com
Most likely, this study will be the first-ever human clinical trial exposure to a Radiopharm therapeutic compound. The trial is pending ethics approval from Australian authorities.
As per the signed Letter of Intent, Radiopharm will deploy its novel radiopharmaceutical (RAD204) targeting PDL/1-positive lung cancer in patients at Australian clinical research centres secured by GenesisCare. If successful, the trial will set the stage for expanded development in lung cancer patients whose cancer is sensitive to treatment with this type of immunotherapy.
The Company believes that there is potential for the treatment to be the “first in class” radiopharmaceutical therapy targeting PDL1.
“We are proud to have entered an LOI with GenesisCare, Australia’s largest provider of integrated cancer care, to support a trial for our innovative radiopharmaceutical therapy targeting non-small cell lung cancer, pending ethics approval from Australian authorities. This is currently an area of high unmet need, and we are hopeful of bringing a first in class treatment to the market that will greatly improve patient outcomes. The phase 1 trial is an important milestone on the path to making this a reality,” said Radiopharm’s CEO & Managing Director Riccardo Canevari.
With centres at over 440 locations across Australia, UK, US, and Spain, GenesisCare has grown to be a global provider of integrated oncology care. The innovation programs of the firm aim to bring novel therapies and precision medicine to more cancer patients in need to achieve the best possible life outcomes.
Kris Barooshian, Senior Vice President of Research and Insights at GenesisCare, said “GenesisCare’s Contract Research Organisation and Site Research Organisation are delighted to be partnering with Radiopharm Theranostics on this clinical trial that may bring hope to thousands of Australians living with non-small cell lung cancer.”
Stock information: RAD shares were trading at AU$0.260 on the Australian Securities Exchange (ASX) midday on 24 March 2022. The Company has a market capitalisation of AU$63.81 million.
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and